Evidence map›Paper›PMID 25243063›Full record

ArticleRSC advances2014

Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells.

Piwen Wang, Bin Wang, Seyung Chung, Yanyuan Wu, Susanne M Henning, Jaydutt V Vadgama

Abstract read
In one paragraph

Article in RSC advances, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Arctigenin: pharmacology, total synthesis, and progress in structure modification.Journal of enzyme inhibition and medicinal chemistry · 2022
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Is Curcumin the Answer to Future Chemotherapy Cocktail?Molecules (Basel, Switzerland) · 2021
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Piwen WangDivision of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA ; Center for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Bin WangDivision of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.
Seyung ChungDivision of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.
Yanyuan WuDivision of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA ; David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Susanne M HenningCenter for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Jaydutt V VadgamaDivision of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA ; David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Charles R. Drew University of Medicine and Science · USCenter for Human Genetics · USUniversity of California System · US

Funding

Workshop for Junior Biostatisticians in Health ResearchU54MD007598 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI Jaydutt V. Vadgama · 2012 to 2026
$60.0M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Supporting African American Churches to Promote Cancer ScreeningU54CA143931 · NCI · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI VADGAMA, JAYDUTT V. · 2009 to 2022
$19.7M
The CDU-Clinical Research Education and Career Development ProgramR25MD007610 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI Roberto Balbino Vargas · 2012 to 2026
$7.8M
UCLA Clinical and Translational Science InstituteKL2TR000122 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$4.5M
NCATS NIH HHS KL2 TR000122NCATS NIH HHS UL1 TR000124NCI NIH HHS U54 CA143931NIMHD NIH HHS R25 MD007610
6 · The paper itself

Abstract

The low bioavailability of most flavonoids limits their application as anti-carcinogenic agents in humans. A novel approach of treatment with a mixture of bioactive compounds that share molecular anti-carcinogenic targets may enhance the effect on these targets at low concentrations of individual compound, thereby overcoming the limitations of reduced bioavailability. We therefore investigated whether a combination of three natural products arctigenin (Arc), a novel anti-inflammatory lignan from the seeds of

Indexed as

arctigeninbreast cancercombinationCurcumingreen tea polyphenolprostate cancer

Identifiers

PMID25243063
PMCPMC4166488
OpenAlexW1991426573

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.